Live
- 2024 on track to be hottest year on record
- PM Modi’s visit to Solapur: Women applaud ‘Double-Engine’ government’s initiatives
- Nagarkurnool MLA Dr. Kuchukulla Rajesh Reddy Campaigning in Maharashtra Elections
- Wife Kills Husband with Her Lover: Details of Veldanda Murder Case Revealed by SP Gaikwad
- Strict Action on Violations of Food Rights: Telangana Food Commission Chairman Goli Srinivas Reddy
- Smooth Conduct of Group-3 Exams with Strict Security Measures: Collector Badavath Santosh
- Delhi HC orders cancellation of LOC issued against Ashneer Grover, wife
- Shami’s absence a major blow for India in BGT, says Paul Adams
- Will organize protests at borders if attack on minority Hindus in Bangladesh not stopped: Bengal LoP
- Dutch Ambassador Marisa Gerard Meets Telangana CM A. Revanth Reddy in Delhi
Zydus Lifesciences arm gets USFDA tentative approval to market hypertension drug
Zydus Lifesciences
These are the generic equivalent of the reference listed drug Uptravi.It will be manufactured at the groups formulation facility at SEZ, Ahmedabad, the company said.Selexipag is used in adults to treat pulmonary arterial hypertension PAH to delay disease progression and reduce the risk of hospitalisation for PAH.
Zydus Lifesciences on Friday said its subsidiary Zydus Worldwide DMCC has received tentative approval from the US health regulator to market its generic version of Selexipag tablets, used to treat pulmonary arterial hypertension in adults.
The approval by the US Food and Drug Administration (USFDA) is for Selexipag tablets in the strengths of 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg, and 1,600 mcg, the company said in a regulatory filing. These are the generic equivalent of the reference listed drug Uptravi.
It will be manufactured at the group's formulation facility at SEZ, Ahmedabad, the company said.
Selexipag is used in adults to treat pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalisation for PAH. Citing IQVIA MAT March 2022 data, the company said Uptravi tablets had annual sales of USD 551 million in the US.
The group now has 331 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in FY2003-04, Zydus said.
